Integra LifeSciences (NASDAQ:IART) Shares Gap Down – Here’s What Happened

Integra LifeSciences Holdings Corporation (NASDAQ:IART) gapped down before the market opened on Wednesday . The stock had previously closed at $19.76, but opened at $18.51. Integra LifeSciences shares last traded at $18.4080, with a volume of 114,181 shares traded.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported second-quarter adjusted earnings of $0.56 per share, exceeding the $0.48 analyst consensus and rising from $0.45 a year earlier. Integra LifeSciences Q2 Earnings Top Estimates
• Positive Sentiment: Second-quarter revenue was $418.76 million, slightly above the $417.54 million consensus estimate, indicating sales were at least tracking expectations. Integra Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management forecast third-quarter EPS of $0.53–$0.61 and revenue of $410 million–$425 million, compared with analyst estimates of $0.56 and $417.3 million, respectively. The ranges imply results could modestly exceed or fall short of expectations.
• Neutral Sentiment: Full-year 2026 guidance remained centered on consensus, with EPS of $2.40–$2.50 versus the $2.45 estimate and revenue of approximately $1.7 billion. This suggests management did not deliver a significant outlook upgrade despite the quarterly earnings beat. Integra Second Quarter 2026 Financial Results
• Negative Sentiment: The company reported a negative net margin of 30.15%, a potential concern for investors even though return on equity remained positive. The stock also faces a cautious signal from UBS, which initiated coverage with a Neutral rating and a $19 price target.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IART shares. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Thursday, June 18th. BMO Capital Markets started coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target on the stock. Truist Financial raised their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, UBS Group assumed coverage on shares of Integra LifeSciences in a report on Tuesday. They set a “neutral” rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $18.43.

Integra LifeSciences Price Performance

The stock has a market capitalization of $1.38 billion, a PE ratio of -2.71, a P/E/G ratio of 1.35 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The firm’s 50 day simple moving average is $17.61 and its 200 day simple moving average is $13.41.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after acquiring an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Integra LifeSciences in the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. lifted its position in Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after purchasing an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Integra LifeSciences by 23.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Integra LifeSciences during the second quarter valued at approximately $491,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.